Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEL | Q05823 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.45 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.45 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.45 |
| ▸ | LDHA | P00338 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | FBP1 | P09467 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.45 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.45 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.45 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22340091 | 0.93 | POLB (0.55) | RNASELPOLBP2RY1DTYMK | |
| SCHEMBL22340083 | 0.91 | POLB (0.45) | POLBDNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL22340089 | 0.91 | RNASEL (0.46) | RNASELPOLBDTYMK | |
| SCHEMBL24060484 | 0.90 | RNASEL (0.45) | RNASELDTYMK | |
| SCHEMBL22340271 | 0.88 | POLB (0.53) | POLBP2RY2P2RY1DTYMK | |
| SCHEMBL21133333 | 0.87 | RNASEL (0.58) | RNASELPOLBDNPH1PRKAB2TRPM2 | |
| SCHEMBL22340220 | 0.87 | DTYMK (0.44) | RNASELPOLBP2RY1DTYMK | |
| SCHEMBL22930656 | 0.86 | POLB (0.54) | RNASELPOLBP2RY2 | |
| SCHEMBL22340218 | 0.85 | IMPDH2 (0.44) | POLBP2RY1TAS1R3TAS1R1 | |
| SCHEMBL22340261 | 0.84 | POLB (0.54) | POLBDNPH1PRKAB2TRPM2LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10953032-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200253997-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200253997-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, NTPCR, CD38 | RNASEL 692/4885POLB 32/4885DNPH1 2002/4885 |
| US-10953032-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | RNASEL 692/4885POLB 32/4885DNPH1 2002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.